In this age group, it may be more appropriate to focus resources on reflex BRCA1/2 and HRD tumour testing, with confirmatory germline BRCA1/2 testing reserved for those patients with a tumour-pathogenic variant. This evidence concerns the gene BRCA1 and neoplasm.